A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary)
- Indications Cervical cancer; Non-small cell lung cancer; Oesophageal cancer
- Focus Therapeutic Use
- 13 Jan 2025 New trial record